Diane Bohn, MS, RN, ANP-BC

Articles by Diane Bohn, MS, RN, ANP-BC

Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and collaboration drive the growing integration of SubQ formulations as a convenient and adaptable option in cancer care.

Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the broader adoption of subcutaneous (SubQ) oncology therapies, underscoring the need for coordinated stakeholder collaboration and education to drive integration.

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement models, highlighting the need for collaborative education and flexible care strategies to ensure patient-centered, financially viable implementation.

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer coordination, billing oversight, and nurse retraining to ensure both financial sustainability and safe, efficient patient care.

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical record (EMR) readiness, workflow adaptation, and patient-centered communication to ensure safe, efficient, and individualized care.

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot strategies—combined with strong leadership and patient education—to enhance efficiency, staff engagement, and the overall care experience.

Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with pharmacy and therapeutics committees balancing patient benefit, operational feasibility, and financial risk to guide adoption.

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health care efficiency, and clinical workflows in light of recent FDA approvals and evolving pharmaceutical strategies.

Latest Updated Articles



    Brand Logo

    259 Prospect Plains Rd, Bldg H
    Monroe, NJ 08831

    609-716-7777

    © 2025 MJH Life Sciences®

    All rights reserved.

    Secondary Brand Logo